Evercore ISI downgraded Chinook Therapeutics (KDNY) to In Line from Outperform with a $40 price target after Novartis (NVS) agreed to acquire Chinook for $3.2B upfront plus contingent value rights, or CVRs, worth up to $320M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KDNY:
- Chinook Therapeutics downgraded to Hold from Buy at Stifel
- Chinook Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Chinook downgraded to Market Perform from Outperform at SVB Securities
- Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
- Lexicon has ‘only un-partnered asset’ in SGLT2i space, says Piper